	Association of XPD Gene Polymorphisms with Cutaneous Melanoma Risk: A Meta-Analysis and Trial Sequence Evaluation. Cancer Invest Farnoush N, Rahmani A, Khosravi-Mashizi M, Shiri A, Dastgheib SA, Barahman M, Shirinzadeh-Dastgiri A, Vakili-Ojarood M, Naseri A, Asadian F, Aghasipour M, Aghili K, Neamatzadeh H. PMID: 42165380 [PubMed - as supplied by publisher]
	Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review. Hum Vaccin Immunother Cohen JE, Mehmi I, Avner M, Moyers J, Hamid O. PMID: 42163062 [PubMed - indexed for MEDLINE]
	Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma. Ann Oncol Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff MM, Joshua AM, Ochsenreither S, Gastaud L, Curti BD, Demidov LV, Milhem MM, Chmielowski B, Kendra KL, Ascierto PA, Bernicker EH, Carvajal RD, Collins L, Lockwood S, Patel JM, Hamid OA, Baurain JF, Nathan PD. PMID: 42162665 [PubMed - as supplied by publisher]
	HLA Class II Alleles DRB111:01 and DQB103:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab. AAPS J Rajendran S, Gutierrez AH, Chien MS, Tang T, Gokemeijer J, Forman D, De Groot AS, Jawa V, Hamuro L. PMID: 42162441 [PubMed - indexed for MEDLINE]
	Payer-Negotiated Prices in the Diagnosis and Management of Cutaneous Melanoma in 2025. JCO Oncol Pract Bian MY, Nassief G, Ruesch V, Gorthi V, Chino F, Bordeaux JS, Rothermel LD. PMID: 42160698 [PubMed - as supplied by publisher]
	Imiquimod for Melanoma in Situ and Lentigo Maligna: A Systematic Review. Dermatol Surg Fay JW, Kimball KM, Hartman NW, Kuceki G. PMID: 42160516 [PubMed - as supplied by publisher]
	Giant Dedifferentiated Melanoma Mimicking Soft Tissue Sarcoma with Loss of Conventional Melanocytic Markers: Diagnostic Utility of PRAME and BRAF V600E Immunohistochemistry. Clin Exp Dermatol Usui M, Ikuno Y, Hirano S, Kobayashi Y, Koike T, Maeda Y, Yamaguchi A, Takahashi T, Arakawa A, Noujima M, Fujimoto N. PMID: 42159209 [PubMed - as supplied by publisher]
	Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential. Front Oncol Spatola GF, Pitruzzella A, Listro AG, Valenti C, Scalisi M, Milia F, Listro P, Zingales F, Ferranti GM, Listro M, Belmonte B, Picone D, Intili G, Uzzo ML. PMID: 42158425 [PubMed]
	Metastatic melanoma with heterologous bone after neoadjuvant immunotherapy: diagnostic insights. Pathologica Pepe L, Fiorentino V, Ieni A, Santarpia M, Fazio A, Vaccaro M, Borgia F, Ferrara G, Lentini M. PMID: 42157743 [PubMed - indexed for MEDLINE]
	Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma. BMJ Case Rep Matar R, Abu Zeinah K, Modi T, Ducharme-Smith A. PMID: 42156103 [PubMed - indexed for MEDLINE]
	MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities. Cancer Sci Shah B, Mayhew MM, Sellers J, Witt RG. PMID: 42153615 [PubMed - as supplied by publisher]
	Evolution of Thiosemicarbazones: From First- to Second-Generation Metal Chelators and Their Reactive Oxygen Species-Mediated Effects in Melanoma. ChemistryOpen Alim R, Andrew SD, Parkinson CJ. PMID: 42152802 [PubMed - indexed for MEDLINE]
	Exploring the paradoxical association of sun exposure and melanoma-specific mortality: The Norwegian Women and Health (NOWAC) Study. Eur J Cancer Perrier F, Ahimbisibwe A, Valberg M, Green AC, Ghiasvand R, Rueegg CS, Weiderpass E, Braaten TB, Robsahm TE, Veierød MB. PMID: 42150442 [PubMed - as supplied by publisher]
	Phytosomes against melanoma: disrupting molecular pathways with targeted phytochemical delivery. Discov Nano Uniyal P, Bhardwaj N, Raina D. PMID: 42149379 [PubMed]
	Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma. Clin Cancer Res Granhøj JS, Mannering SMH, Madsen K, W Hendel H, Draghi A, Jedema I, Lievense J, Nijenhuis C, Nuijen B, V Zon M, W Rohaan M, Tak WS, Klobuch S, Borch TH, Met Ö, Haanen J, Donia M, Svane IM. PMID: 42149143 [PubMed - as supplied by publisher]
	Zerumbone Induced ROS-Mediated Autophagic Cell Death in Human Melanoma Cells: An InÂ Vitro and InÂ Vivo Study. Biofactors Chen SJ, Hseu YC, Zhang YM, Pandey S, Bhat AA, Li YH, Huang PJ, Yang HL, Hseu JH. PMID: 42144730 [PubMed - indexed for MEDLINE]
	Higher Dermatologist Density Is Associated with Lower Proportions of Late-Stage Melanoma: An Ecological Study of the State Cancer Profiles. J Am Acad Dermatol Kasheri E, Dan J, Nouri K. PMID: 42144199 [PubMed - as supplied by publisher]
	Trends and projections of the melanoma burden in G20 countries: A comprehensive analysis from the Global Burden of Disease Study, 1990-2023. J Am Acad Dermatol Yu H, Ma J, Lin P, Li H. PMID: 42142593 [PubMed - as supplied by publisher]
	A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma. Nat Commun Mao L, Lai Y, Zheng H, Cui M, Li L, Liu Z, Zhou H, Sun L, Li C, Wei X, Gu J, Bai X, Kong Y, Cui C, Chi Z, Sheng X, Lian B, Li S, Yan X, Tang B, Li J, Zhou L, Wang X, Guo J, Dai J, Si L. PMID: 42140948 [PubMed - as supplied by publisher]
	Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. J Immunother Cancer Lee JB, Baek S, Kim DK, Kwon BE, Ahn JS, Nagasaka M, Davar D, Park H, Kim H, Im J, Yang J, Yang E, Shin GH, Choi S, Kwon JE, Kim JM, Kang SY, Kim Y, Park SY, Kim JH, Oh HS, Chalita M, Min A, Cho BC. PMID: 42140743 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 45641

Page 1 of 2283



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy